Overlapping network meta‐analyses on psoriasis systemic treatments: an overview, quantity does not make quality

Network Meta‐analyses (NMAs) have become successful in addressing gaps in the comparative effectiveness of systemic treatments in moderate‐to‐severe psoriasis. However, their increasing number carries both a risk of overlap and reproducibility issues that can hamper clinical decision‐making. In this overview, we aimed to assess redundancy across these NMAs and to describe their characteristics. We considered all systematic reviews with NMAs of randomized controlled trials that included adult patients with moderate‐to‐severe psoriasis and that evaluated the efficacy and/or safety of systemic treatments compared with placebo or with an active comparator. Our main outcome was the number per year of redundant NMAs and the extent of their overlap. We also described their features, especially, the confidence in the results of the reviews, the studies’ funding and the presence of spin (a description that overstates efficacy and/or understates harm), reporting issues and methodological characteristics.